Status:
COMPLETED
Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Lead Sponsor:
The Catholic University of Korea
Conditions:
Chronic Prostatitis
Chronic Pelvic Pain Syndrome
Eligibility:
MALE
Brief Summary
Roxithromycin is effective in the treatment of intracellular organisms, including chlamydia and mycoplasma, and exhibits anti-inflammatory and immunomodulatory effects on respiratory diseases. To expl...
Detailed Description
A total of 75 patients with CP/CPPS were randomized to three groups in open-label: group 1, ciprofloxacin; group 2, aceclofenac; and group 3, roxithromycin. The patients were treated for 4 weeks and w...
Eligibility Criteria
Inclusion
- Diagnosis of category IIIa of IIIb chronic prostatitis
- NIH-CPSI (National Institute of Health Chronic Prostatitis Symptom Index) score ≥ 15
Exclusion
- Urinary tract infection or uropathogen within the past 12 months
- Serious medical problems
- NIH consensus exclusion criteria13 (presence of active urethritis, urogenital cancer, urinary tract disease, functionally significant urethral stricture, neurological disease affecting the bladder, etc.)
- Drug therapy that might affect lower urinary tract functions within the past 3 months
Key Trial Info
Start Date :
March 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT01843946
Start Date
March 1 2011
End Date
July 1 2012
Last Update
May 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Catholic University of Korea, St. Vincent's Hospital
Suwon, South Korea, 442-723